RESUMO
BACKGROUND: Headache is a common, yet challenging symptom to evaluate given its wide range of clinical presentations and different etiologies. For centuries, conceptual understanding of headache causation has been attributed to anatomic abnormalities of the nose and paranasal sinuses. METHODS: Structured literature review. RESULTS: The number of cases, categorized as migraines or other primary headaches, misdiagnosed as a "sinus headache" is high in the literature, ranging from 50 to 80%. The potential mechanisms for rhinogenic headaches were classically described as pain secondary to prolonged mucosal contact points, hypoxia in the paranasal sinuses secondary to poor ventilation, or pressure caused by the growth of nasal polyps. Additionally, other mechanisms were described and are still being studied. Corrective surgery for mucosal contact points in the nasal cavity is deemed necessary for relieving the headache, although patient outcomes are variable. CONCLUSION: Delay in proper diagnosis and treatment negatively impact patient quality of life. Most cases of "sinus headache" or "rhinogenic headache" seen in clinical practice are in fact misdiagnosed as either primary headaches or migraines. Because of increased misdiagnoses, Otolaryngologists should establish a direct and precise diagnosis congruent with a chief complaint being a headache. Vital information such as a good clinical history, well-performed nasal endoscopy, and occasional CT scan may decrease misdiagnosis probability.
Assuntos
Cefaleia/etiologia , Cefaleia/terapia , Erros de Diagnóstico/prevenção & controle , Endoscopia , Cefaleia/diagnóstico , Cefaleia/patologia , Humanos , Transtornos de Enxaqueca , Cavidade Nasal/anormalidades , Pólipos Nasais/complicações , Seios Paranasais/anormalidades , Tomografia Computadorizada por Raios XRESUMO
BACKGROUND: Thyroid dysfunction is associated with the use of tyrosine kinase inhibitors (TKI) in people. HYPOTHESIS/OBJECTIVES: To determine whether dysfunction in the hypothalamic-pituitary-thyroid axis occurs in dogs receiving the TKI, toceranib phosphate. ANIMALS: Forty-three client-owned dogs with cancer. METHODS: Prospective, observational study. Concentrations of total thyroxine (TT4), free thyroxine (FT4), total triiodothyronine (TT3), and thyroid-stimulating hormone (TSH) were evaluated on day 0, 30, and 90. Dogs also were evaluated for the presence of thyroglobulin autoantibodies. RESULTS: The proportion of dogs with low TT4, low FT4, low TT3, high TSH, or primary hypothyroidism (increased TSH and decreased TT4, FT4 or both) did not change over 90 days. Hormone concentrations remained within laboratory reference intervals, but FT4 (P = 0.0032) and TSH (P < 0.0001) changed over time. Mean FT4 was 1.22 ng/dL (95% confidence interval [CI], 1.10-1.34) on day 0 and 1.00 ng/dL (95% CI, 0.86-1.16) on day 90. Mean TSH was 0.17 ng/mL (95% CI, 0.13-0.23) on day 0 and 0.34 ng/mL (95% CI, 0.24-0.48) on day 90. Furthermore, TT4/TT3 ratio also changed over time (P = 0.0086). Mean TT4/TT3 ratio was 2.57 (95% CI, 2.26-2.88) on day 0 and 2.02 on day 90 (95% CI, 1.61-2.44). Thyroglobulin autoantibodies were not detected in any dog. CONCLUSIONS AND CLINICAL IMPORTANCE: Toceranib phosphate can disrupt the hypothalamic-pituitary-thyroid axis in dogs. Periodic evaluation of TT4, FT4, TT3, and TSH should be carried out in dogs receiving long-term treatment with this medication.
Assuntos
Doenças do Cão/tratamento farmacológico , Hipotálamo/efeitos dos fármacos , Indóis/efeitos adversos , Neoplasias/veterinária , Hipófise/efeitos dos fármacos , Pirróis/efeitos adversos , Glândula Tireoide/efeitos dos fármacos , Animais , Autoanticorpos , Cães , Feminino , Hipotireoidismo/veterinária , Indóis/uso terapêutico , Masculino , Neoplasias/tratamento farmacológico , Estudos Prospectivos , Pirróis/uso terapêutico , Tireoglobulina/imunologia , Tireotropina/sangue , Tiroxina/sangue , Tri-Iodotironina/sangueRESUMO
Recent evidence in in vitro and in vivo models suggests that sulforaphane (SFN), found in raw cruciferous vegetables, may have utility in chemoprevention, as an antineoplastic agent and as a free radical scavenger. The effects of SFN alone or with doxorubicin on cell viability were examined, as well as cell cycle kinetics, invasion capabilities and apoptosis in three canine osteosarcoma cell line (D17, OS 2.4 and HMPOS). Results showed that SFN could not induce cell death at potentially physiological concentrations (<50 µM), but significantly diminished cell invasion and downregulation of focal adhesion kinase (FAK) signaling. Modest cell cycle changes were observed in each cell line. When doxorubicin was used in conjunction with SFN, there was a protective effect to doxorubicin-induced cytotoxicity in D17 and OS 2.4 cells. Further studies examining SFN as a supplement are warranted, particularly in light of pro-proliferative and cytoprotective properties in canine osteosarcoma.
Assuntos
Anticarcinógenos/uso terapêutico , Neoplasias Ósseas/veterinária , Doenças do Cão/tratamento farmacológico , Isotiocianatos/uso terapêutico , Osteossarcoma/veterinária , Animais , Antibióticos Antineoplásicos/administração & dosagem , Antibióticos Antineoplásicos/uso terapêutico , Anticarcinógenos/administração & dosagem , Apoptose/efeitos dos fármacos , Neoplasias Ósseas/tratamento farmacológico , Neoplasias Ósseas/patologia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Doenças do Cão/patologia , Cães , Doxorrubicina/administração & dosagem , Doxorrubicina/uso terapêutico , Quimioterapia Combinada , Isotiocianatos/administração & dosagem , Invasividade Neoplásica/prevenção & controle , Osteossarcoma/tratamento farmacológico , Osteossarcoma/patologia , SulfóxidosRESUMO
One of the primary objectives of the Oncology Pathology Working Group (OPWG), a joint initiative of the Veterinary Cancer Society and the American College of Veterinary Pathologists, is for oncologists and pathologists to collaboratively generate consensus documents to standardize aspects of and provide guidelines for oncologic pathology. Consensus is established through review of relevant peer-reviewed literature relative to a subgroup's particular focus. In this document, the authors provide descriptions of the literature reviewed, the review process, and a summary of the information gathered on immunocytochemistry. The intent of this publication is to help educate practitioners and pathologists on the process of immunocytochemistry and to provide a guide for the use of this technique in veterinary medicine. This document represents the opinions of the working group and the authors and does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society.